These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35416391)

  • 21. Reconstructed human keloid models show heterogeneity within keloid scars.
    Limandjaja GC; van den Broek LJ; Waaijman T; Breetveld M; Monstrey S; Scheper RJ; Niessen FB; Gibbs S
    Arch Dermatol Res; 2018 Dec; 310(10):815-826. PubMed ID: 30370495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of the anti-allergic agent avil on abnormal scar fibroblasts.
    Venugopal J; Ramakrishnan M; Habibullah CM; Babu M
    Burns; 1999 May; 25(3):223-8. PubMed ID: 10323606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of Bcl-2, p53, c-jun and c-fos protooncogenes in keloids and hypertrophic scars.
    Teofoli P; Barduagni S; Ribuffo M; Campanella A; De Pita' O; Puddu P
    J Dermatol Sci; 1999 Dec; 22(1):31-7. PubMed ID: 10651227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased epidermal thickness and abnormal epidermal differentiation in keloid scars.
    Limandjaja GC; van den Broek LJ; Waaijman T; van Veen HA; Everts V; Monstrey S; Scheper RJ; Niessen FB; Gibbs S
    Br J Dermatol; 2017 Jan; 176(1):116-126. PubMed ID: 27377288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epithelial-mesenchymal transition in the formation of hypertrophic scars and keloids.
    Yuan FL; Sun ZL; Feng Y; Liu SY; Du Y; Yu S; Yang ML; Lv GZ
    J Cell Physiol; 2019 Dec; 234(12):21662-21669. PubMed ID: 31106425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Wnt Signaling Pathway Proteins in Scar, Hypertrophic Scar, and Keloid: Evidence for a Continuum?
    Chaudet KM; Goyal A; Veprauskas KR; Nazarian RM
    Am J Dermatopathol; 2020 Nov; 42(11):842-847. PubMed ID: 32310858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of protease-activated receptor-1 and -2 in human scar formation.
    Materazzi S; Pellerito S; Di Serio C; Paglierani M; Naldini A; Ardinghi C; Carraro F; Geppetti P; Cirino G; Santucci M; Tarantini F; Massi D
    J Pathol; 2007 Aug; 212(4):440-9. PubMed ID: 17597495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in collagen architecture between keloid, hypertrophic scar, normotrophic scar, and normal skin: An objective histopathological analysis.
    Verhaegen PD; van Zuijlen PP; Pennings NM; van Marle J; Niessen FB; van der Horst CM; Middelkoop E
    Wound Repair Regen; 2009; 17(5):649-56. PubMed ID: 19769718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemical evaluation of COX-1 and COX-2 expression in keloid and hypertrophic scar.
    Abdou AG; Maraee AH; Saif HF
    Am J Dermatopathol; 2014 Apr; 36(4):311-7. PubMed ID: 24061401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence-based management of keloids and hypertrophic scars in dermatology.
    Kim EY; Hussain A; Khachemoune A
    Arch Dermatol Res; 2023 Aug; 315(6):1487-1495. PubMed ID: 36504113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Hyperplastic scars and keloids. Part I: basics and prevention].
    Baisch A; Riedel F
    HNO; 2006 Nov; 54(11):893-904; quiz 905. PubMed ID: 17041777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Expression of microRNA-296 in rabbit hypertrophic scars and its role to human fibroblasts].
    Guo BY; Lin F; Bai ZM; Tao K; Wang HY
    Zhonghua Shao Shang Za Zhi; 2021 Aug; 37(8):725-730. PubMed ID: 34404160
    [No Abstract]   [Full Text] [Related]  

  • 33. Matrix metalloproteinase-2 and -9 activities in human keloids, hypertrophic and atrophic scars: a pilot study.
    Tanriverdi-Akhisaroglu S; Menderes A; Oktay G
    Cell Biochem Funct; 2009 Mar; 27(2):81-7. PubMed ID: 19165813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The expression of tenascin-C mRNA in keloids and hypertrophic scars].
    Han CM; He XJ; Ma Q
    Zhonghua Zheng Xing Wai Ke Za Zhi; 2005 Jan; 21(1):40-3. PubMed ID: 15844597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic susceptibility to keloid disease and hypertrophic scarring: transforming growth factor beta1 common polymorphisms and plasma levels.
    Bayat A; Bock O; Mrowietz U; Ollier WE; Ferguson MW
    Plast Reconstr Surg; 2003 Feb; 111(2):535-43; discussion 544-6. PubMed ID: 12560674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heterogeneity of human fibroblasts isolated from hypertrophic scar.
    Ţuţuianu R; Roşca AM; Florea G; Prună V; Iacomi DM; Rădulescu LA; Neagu TP; Lascăr I; Titorencu ID
    Rom J Morphol Embryol; 2019; 60(3):793-802. PubMed ID: 31912089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Keloid and Hypertrophic Scars Are the Result of Chronic Inflammation in the Reticular Dermis.
    Ogawa R
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28287424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exclusive expression of KANK4 promotes myofibroblast mobility in keloid tissues.
    Oishi M; Shinjo K; Takanari K; Muraoka A; Suzuki MM; Kanbe M; Higuchi S; Ebisawa K; Hashikawa K; Kamei Y; Kondo Y
    Sci Rep; 2024 Apr; 14(1):8725. PubMed ID: 38622256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Variations of lipid peroxidation products and copper, zinc-superoxide dismutase in pathological scars].
    Li W; Cen Y; Wang H; Chen W; Liu D
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Jul; 22(7):838-41. PubMed ID: 18681286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Keloids and Hypertrophic Scars: Pathophysiology, Classification, and Treatment.
    Berman B; Maderal A; Raphael B
    Dermatol Surg; 2017 Jan; 43 Suppl 1():S3-S18. PubMed ID: 27347634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.